Federal grants to Evoq Therapeutics, Inc.
Evoq Therapeutics, Inc. in Ann Arbor, Michigan received $4.8 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was National Center for Advancing Translational Sciences, with $2.0 million. In fiscal 2025 it was awarded $2.0 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$4.8 million
- Awards4
- Awarded in FY 2025$2.0 million
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 1 | $287,733 |
| FY 2023 | 1 | $761,809 |
| FY 2024 | 2 | $1.8 million |
| FY 2025 | 2 | $2.0 million |
Programs that fund Evoq Therapeutics, Inc.
| Program | Awards | Amount |
|---|---|---|
| National Center for Advancing Translational Sciences | 1 | $2.0 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 1 | $1.5 million |
| Allergy and Infectious Diseases Research | 2 | $1.3 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $4.8 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Novel immunotherapy against mog antibody disease - project summary/abstract myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD) is a rare disease characterized as a neurological, inflammatory, demyelinating disorder of the central nervous system. The symptoms of mogad include vision l | National Center for Advancing Translational Sciences | July 11, 2024 | $2.0 million |
| New approach for immune modulation against T1D - project summary/abstract type 1 diabetes (T1D) is an autoimmune disease that affects 1 in 300 people by the age of 18 in the us. T1D is characterized by acute onset of hyperglycemia resulting from immune-mediated destruction of the insulin- producing | Diabetes, Digestive, and Kidney Diseases Extramural Research | September 19, 2023 | $1.5 million |
| Nanodiscs for immune modulation in celiac disease - project summary/abstract celiac disease (CED) affects approximately 1% of the global population, with gluten exposure leading to symptoms such as nausea, vomiting, and damage to the small intestine. Although a lifelong gluten-free diet is the curre | Allergy and Infectious Diseases Research | September 19, 2025 | $1.1 million |
| Novel immunotherapy against mog antibody disease - project summary/abstract myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD) is a rare, neurological, immune- mediated inflammatory, demyelinating disorder of the central nervous system. The symptoms of mogad include vision loss, symp | Allergy and Infectious Diseases Research | July 15, 2022 | $287,733 |
Questions people ask
How much federal grant money does Evoq Therapeutics, Inc. get?
$4.8 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Evoq Therapeutics, Inc. the most?
The Department of Health and Human Services, with $4.8 million in 4 awards.
What is Evoq Therapeutics, Inc.'s largest federal grant?
$2.0 million under National Center for Advancing Translational Sciences, with its first action in the period on July 11, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Evoq Therapeutics, Inc.?
Its largest are National Center for Advancing Translational Sciences, Diabetes, Digestive, and Kidney Diseases Extramural Research and Allergy and Infectious Diseases Research.
Other grant recipients in Ann Arbor
- Regents of the University of Michigan
- National Center for Manufacturing Sciences Inc
- Ann Arbor Area Transportation Authority
- County of Washtenaw
- Washtenaw Community College
- Great Lakes Commission
- Great Lakes Fishery Commission
- Washtenaw Intermediate School District
Largest federal grant recipients in Michigan · Federal grants in Michigan